Complete financial analysis of HilleVax, Inc. (HLVX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HilleVax, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- KUWAZAWA Holdings Corporation (8104.T) Income Statement Analysis – Financial Results
- Lumen Technologies, Inc. (0HVP.L) Income Statement Analysis – Financial Results
- Premium Beverage Group, Inc. (PBEV) Income Statement Analysis – Financial Results
- Aroundtown SA (AT1.DE) Income Statement Analysis – Financial Results
- Softline AG (SFD1.DE) Income Statement Analysis – Financial Results
HilleVax, Inc. (HLVX)
About HilleVax, Inc.
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.16M | 2.25M | 3.00K | 0.00 | 0.00 |
| Gross Profit | -2.16M | -2.25M | -3.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 106.68M | 45.91M | 10.01M | 0.00 | 0.00 |
| General & Administrative | 26.66M | 16.71M | 5.76M | 1.30M | 633.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 632.37K |
| SG&A | 26.66M | 16.71M | 5.76M | 1.30M | 633.00K |
| Other Expenses | 0.00 | -94.70M | -20.23M | -779.00K | 0.00 |
| Operating Expenses | 133.35M | 62.61M | 15.77M | 1.30M | 633.00K |
| Cost & Expenses | 133.35M | 62.61M | 15.77M | 1.30M | 633.00K |
| Interest Income | 9.71M | 3.88M | 2.84K | 29.00 | 9.00 |
| Interest Expense | 2.39M | 3.41M | 2.84M | 29.00K | 9.00K |
| Depreciation & Amortization | 879.00K | 2.25M | 3.00K | 1.30M | 633.00K |
| EBITDA | -132.47M | -65.11M | -99.56M | -2.07M | -31.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -133.35M | -65.11M | -53.43M | -1.30M | -633.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 9.78M | -94.70M | -48.98M | -808.00K | -40.00K |
| Income Before Tax | -123.57M | -159.81M | -102.41M | -2.10M | -673.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 97.20M | -17.38M | 29.00K | -633.00 |
| Net Income | -123.57M | -257.01M | -85.03M | -2.13M | -673.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.04 | -6.83 | -2.82 | -0.07 | -0.02 |
| EPS Diluted | -3.04 | -6.83 | -2.82 | -0.07 | -0.02 |
| Weighted Avg Shares Out | 40.60M | 37.66M | 30.19M | 30.19M | 30.19M |
| Weighted Avg Shares Out (Dil) | 40.60M | 37.66M | 30.19M | 30.19M | 30.19M |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ:HLVX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, July 14, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. (“HilleVax” or “the Company”) (NASDAQ: HLVX). Investors who purchased HilleVax securities are encouraged...
HKVX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into HilleVax, Inc. and Encourages Shareholders to Contact the Firm!
NEW YORK CITY, NY / ACCESSWIRE / July 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to...
The Schall Law Firm Encourages HLVX Stakeholders To Join Its Probe Into Suspected Securities Fraud At HilleVax Inc
LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations...
The Schall Law Firm Invites HLVX Stakeholders To Participate In Its Investigation Into Alleged Securities Fraud At HilleVax Inc
LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. (“HilleVax” or the “Company”) (NASDAQ: HLVX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
HKVX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into HilleVax, Inc. and Encourages Shareholders to Contact the Firm!
NEW YORK CITY, NY / ACCESSWIRE / July 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to...
Stakeholders Of HLVX Are Urged To Join The Schall Law Firm's Investigation Of Securities Fraud At HilleVax Inc
LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations...
Down -88.84% in 4 Weeks, Here's Why HilleVax (HLVX) Looks Ripe for a Turnaround
HilleVax (HLVX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the...
HKVX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into HilleVax, Inc. and Encourages Investors to Contact the Firm!
NEW YORK CITY, NY / ACCESSWIRE / July 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to...
Source: https://incomestatements.info
Category: Stock Reports